Last updated July 17, 2026
Key finding
Resmetirom-treated patients (100 mg) with weight loss (≥5%) had higher rates of MASH resolution (56.6% vs. 33.8%).
This study evaluated the efficacy of Resmetirom in patients with metabolic dysfunction associated steatohepatitis and type 2 diabetes, finding significant improvements in liver health outcomes.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the efficacy of Resmetirom in patients with metabolic dysfunction associated steatohepatitis and type 2 diabetes, finding significant improvements in liver health outcomes.
These findings are clinically significant as they suggest that Resmetirom could be an effective treatment option for patients with metabolic dysfunction associated steatohepatitis and type 2 diabetes, particularly for those who can achieve weight loss, potentially reducing the risk of liver-related complications.
Unclear effectiveness for some outcomes due to lack of p-values. Results may not be generalizable to all populations with MASH. Limited sample size may affect the robustness of findings.
Published in
Publication details and source links for this paper.
Mazen N, Mary R, Rebecca T, et al. Efficacy of Resmetirom in Patients with Metabolic Dysfunction Associated Steatohepatitis and Type 2 Diabetes. Alimentary Pharmacology & Therapeutics. 2025;62(11-12):1089-1099. doi:10.1111/apt.70382
Resmetirom-treated patients with weight loss (≥5%) had a 56.6% MASH resolution rate compared to 33.8% in placebo.
Fibrosis improvement was observed in 40.6% of Resmetirom-treated patients with weight loss versus 31.5% without.
MRI-PDFF reduction was -69% in Resmetirom patients with weight loss compared to -46% in those with less weight loss.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Resmetirom (100 mg) and Change in MRI-proton density fat fraction (MRI-PDFF), Fibrosis improvement percentage, Liver stiffness measure, and 1 more.
This study contributes evidence to
Primary intervention
Resmetirom (100 mg)
Primary outcomes
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
0
Related topics
4
Evidence pairs
0
Related studies
Core evidence
The primary outcomes reported in this study.
Resmetirom (100 mg) → Change in MRI-proton density fat fraction (MRI-PDFF)
Resmetirom (100 mg) → Change in MRI-proton density fat fraction (MRI-PDFF)
Resmetirom (100 mg) → Fibrosis improvement percentage
Resmetirom (100 mg) → Fibrosis improvement percentage
Resmetirom (100 mg) → Liver stiffness measure
Resmetirom (100 mg) → Liver stiffness measure
Resmetirom (100 mg) → Resolution of metabolic dysfunction associated steatohepatitis
Resmetirom (100 mg) → Resolution of metabolic dysfunction associated steatohepatitis
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Resmetirom (100 mg) and Fibrosis improvement percentage, Resmetirom (100 mg) and Liver stiffness measure.
This study contributes to the evidence on the following intervention-outcome relationships.
Curated evidence collections and hubs this study is part of.
All studies measuring Fibrosis improvement percentage
Measures Fibrosis improvement percentage as a key outcome.
All studies measuring Liver stiffness measure
Measures Liver stiffness measure as a key outcome.
All studies on Resmetirom (100 mg)
Contributes to Resmetirom (100 mg) evidence base.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Resmetirom (100 mg) appears to improve Change in MRI-proton density fat fraction (MRI-PDFF).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Change in MRI-proton density fat fraction (MRI-PDFF)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Resmetirom (100 mg) appears to improve Fibrosis improvement percentage.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Fibrosis improvement percentage
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Resmetirom (100 mg) appears to improve Liver stiffness measure.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Liver stiffness measure
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Resmetirom (100 mg) appears to improve Resolution of metabolic dysfunction associated steatohepatitis.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Resolution of metabolic dysfunction associated steatohepatitis
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
